You are here

Dapagliflozin effects on biomarkers, symptoms and functional status in patients with heart failure and reduced ejection fraction with and or without diabetes: the DEFINE-HF trial

Wednesday, 18 September 2019, 13:15 - 14:15, Vilanova Hall

Chair: Lars Rydén, SE

M.N. Kosiborod, US: Background and rationale for DEFINE-HF trial

M.E. Nassif, US: DEFINE-HF study design and baseline characteristics

M.N. Kosiborod, US: Effect of dapagaliflozin on the primary outcomes

M.E. Nassif, US: Effect of dapagliflozin on secondary and safety outcomes

M.N. Kosiborod, US: Putting DEFINE-HF in perspective: clinical implications and path forward

Discussion